Key insights
- Arcellx (ACLX) hit an all-time high amid news of its acquisition by Gilead Sciences for $7.8 billion ($115/share + $5 CVR). While the stock initially surged, analysts have since downgraded ACLX, aligning price targets with the acquisition offer. Three analysts have revised earnings upward for the upcoming period. The acquisition news and subsequent analyst actions have a slightly positive influence, reflecting a fair valuation but limited future upside.
Arcellx Inc stock reached an all-time high of $115.13, marking a significant milestone for the biotechnology company with a market capitalization of $6.75 billion. Over the past year, Arcellx Inc has experienced a remarkable 80.7% total return, with year-to-date gains of 76.4%, reflecting strong investor confidence. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value—a consideration for investors evaluating entry points. The company joins other highly-valued stocks trading at premium multiples. The achievement of this all-time high underscores the company’s upward trajectory and market optimism surrounding its innovative approaches in the biotech industry. InvestingPro Tips highlight that three analysts have revised earnings upward for the upcoming period, while the platform’s comprehensive Pro Research Report—available for ACLX and 1,400+ US equities—provides deeper analysis of the company’s growth prospects despite current unprofitability.
In other recent news, Arcellx Inc. has been the subject of multiple analyst downgrades following Gilead Sciences’ announcement of its acquisition of the company. The proposed deal values Arcellx at approximately $7.8 billion, with Gilead offering $115 per share plus a $5 contingent value right tied to future sales milestones. Analysts from TD Cowen, Guggenheim, UBS, Stifel, and Evercore ISI have all downgraded Arcellx’s stock rating, reflecting the acquisition’s impact on the company’s future prospects. Guggenheim adjusted its price target from $120 to $115, aligning with the acquisition offer, while UBS increased its target from $100 to $115. Stifel also lowered its price target to $115 from $127, and Evercore ISI set its target at $115. The downgrades indicate a consensus among analysts that the acquisition offer is fair and appropriately values Arcellx’s potential. These developments come as both companies’ boards have approved the proposed acquisition terms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.